Novaseek Research and Massachusetts Hospital Association (MHA) partner to help hospitals and patients contribute to biomedical research
Boston, MA, January 7, 2016 – Massachusetts Hospital Association (MHA) and Novaseek Research today announced a novel collaboration that will enable Massachusetts-based hospitals and patients to contribute broadly to the advancement of biomedical research. Through this collaboration, MHA member hospitals will leverage Novaseek’s state-of-the art platform to provide researchers in industry and academia with biospecimens and associated clinical data from consenting patients, accelerating research into the diagnosis and treatment of human disease.
Breakthroughs in medicine require the support of patients and healthcare organizations of all sizes. However, many institutions struggle to balance research engagement with their core mission of providing patient care. The Novaseek platform makes contributing to biomedical research easier than ever before by plugging into health information systems at hospitals and labs, and matching data and specimens from consenting patients directly to research needs.
Getting access to clinical data and biospecimens is a chronic problem that continues to delay or derail vital research projects. Novaseek integrates clinical data from multiple healthcare organizations, ensuring that the data is HIPAA-compliant and easy to use in R&D. Novaseek’s platform realizes the potential of the electronic medical record (EMR) by accessing streams of data on thousands of specimens from consenting patients that flow through hospital laboratories each day and that would otherwise be discarded.
It provides researchers with powerful analytics, based on real-world real-time data, and supports project planning and biospecimen accrual projections. Furthermore, the platform enables researchers to specify criteria such as lab values, gender, diagnosis and medication history, and then match these search criteria to biospecimens in the hospitals. Novaseek and its healthcare partners use IRB-approved protocols and patient consents to ensure the ethical conduct of research and respect for all participants.
“We are excited to collaborate with the Massachusetts Hospital Association,” said Dr. Kate Torchilin, CEO, Novaseek Research. “Novaseek was born from the need to bridge the world of life sciences research and the hospital world. Our collaboration with MHA is also strategically aligned with the objectives of the NIH’s Precision Medicine Initiative announced earlier this year.“
“Novaseek Research is a key technology leader who will enable more patients at more hospitals to participate in vital biomedical research,” said Lynn Nicholas, President and CEO of MHA. “As the first hospitals in Massachusetts begin to adopt Novaseek’s platform, we are proud to promote getting consented patient data and samples into the hands of researchers who are developing new treatments and cures , and further strengthening Massachusetts’ preeminent position in life sciences research.”
The Massachusetts Hospital Association (MHA) is a voluntary, not-for-profit organization comprised of hospitals and health systems, related organizations, and other members with a common interest in promoting the good health of the people of the Commonwealth. Through leadership in public advocacy, education, and information, MHA represents and advocates for the collective interests of its members and supports their efforts to provide high quality, cost effective and accessible care. While Massachusetts hospitals and other care providers are facing an era of unprecedented change, MHA members remain committed to their most basic mission: caring for people. To continue to fulfill this mission, the hospitals and health systems of Massachusetts support a set of fundamental values. We believe that the health care system must:
Novaseek connects researchers from industry and academia with healthcare organizations, and enables broad patient participation in medical advances. The Novaseek Clinical Data Network for Research (CDNR) is the industry’s first HIPAA compliant comprehensive platform that enables researchers to access real-world, real-time clinical data and large quantities of high quality biospecimens. Incorporating Novaseek’s CDNR platform across all phases of research and development helps to generate powerful new insights, increases R&D productivity, and decrease risk in the pursuit of new cures. The CDNR platform was developed by experts in drug development, hospital operations and health IT to create a win-win for industry, academia, healthcare providers and patients.